ZLTQ Strong Performance In Q3, Raises 2013 Guidance – USPTO Issues Patent for VGLS’ Peptide for HIV Treatment
Crwepicks Newsletter
(Mailing list information, including instructions, is located at the end of this message.)
ZELTIQ Aesthetics, Inc. (Nasdaq:ZLTQ)
ZLTQ posted total revenue of $29.5 million, representing an increase of 64% year-over year and 12% sequentially.
ZLTQ has increased confidence in its business and has raised its full year revenue guidance to approximately 40% year-over-year growth, up from 20%.
ZLTQ ‘s first commercial product, the CoolSculpting System, is designed to selectively reduce stubborn fat that may not respond to diet or exercise. ZLTQ developed CoolSculpting to safely, noticeably, and measurably reduce the fat layer.
ZLTQ posted its second highest system placement quarter to-date and the company’s highest system placement quarter, ever, in its North America market.
ZLTQ is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform.
More about ZELTIQ Aesthetics, Inc. (Nasdaq:ZLTQ) at www.crwepicks.com/disclaimer
Crwepicks.com
Related posts: